April 2015

New Product - Cosentyx

Cosentyx (secukinumab (rch)) is a recombinant fully human monoclonal antibody selective for interleukin‑17A. Secukinumab is of the IgG1/kappa‑class produced in chinese hamster ovary (CHO) cells. Secukinumab works by targeting IL‑17A and inhibiting its interaction with the IL‑17 receptor, which is expressed on various cell types including keratinocytes. As a result, secukinumab inhibits the release of proinflammatory cytokines, chemokines and mediators of tissue damage and reduces IL‑17A mediated contributions to autoimmune and inflammatory diseases. Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Cosentyx is available as a 150 mg/1 mL solution for subcutaneous injection in a single use prefilled syringe (pack of 2’s) and a single use prefilled pen (pack of 2’s).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au